

=> file medline

FILE 'MEDLINE' ENTERED AT 17:43:38 ON 28 JAN 2003

FILE LAST UPDATED: 28 JAN 2003 (20030128/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/summ2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

*CT = controlled terminology
NT = narrower terms*

=> d que 136

L1	207494	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	METALS, ALKALINE EARTH+NT/CT
L2	8484	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	CATIONS, DIVALENT+NT/CT
L3	28976	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	ZINC/CT
L8	18976	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	POLYETHYLENE GLYCOLS+NT/CT
L12	17247	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	CELLULOSE+NT/CT
L13	16642	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	DEXTRANS+NT/CT
L14	62388	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	GLYCOSAMINOGLYCANS+NT/CT
L20	1563	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	BIOPHARMACEUTICS/CT
L21	10241	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	CHEMISTRY, PHARMACEUTICAL/CT
L22	309013	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	DRUG ADMINISTRATION ROUTES+NT/CT
L23	13586	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	GELS+NT/CT
L24	6891	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	DRUG CARRIERS/CT
L32	6217	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	(L1 OR L2 OR L3) AND (L20 OR L21 OR L22 OR L23 OR L24)
L33	2498	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	L8 AND (L20 OR L21 OR L22 OR L23 OR L24)
L34	8160	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	(L12 OR L13 OR L14) AND (L20 OR L21 OR L22 OR L23 OR L24)
L35	2	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	L32 AND L33 AND L34
<u>L36</u>	1	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	L35 AND HYDROGEL, 1 cite

=> d que 140

L1	207494	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	METALS, ALKALINE EARTH+NT/CT
L2	8484	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	CATIONS, DIVALENT+NT/CT
L3	28976	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	ZINC/CT
L8	18976	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	POLYETHYLENE GLYCOLS+NT/CT
L37	14865	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	POLYSACCHARIDES/CT
L38	320	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	L37 AND (L1 OR L2 OR L3)
L39	4	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	L38 AND L8
<u>L40</u>	1	SEA	FILE=MEDLINE	ABB=ON	PLU=ON	L39 AND HYDROGEL, 1 cite

=> s 136 or 140

L420 2 L36 OR L40 2 cites total for medline

=> file embase

FILE 'EMBASE' ENTERED AT 17:43:40 ON 28 JAN 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE COVERS 1974 TO 16 Jan 2003 (20030116/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 165

```

L49      7929 SEA FILE=EMBASE ABB=ON  PLU=ON  POLYSACCHARIDE/CT
L50      12283 SEA FILE=EMBASE ABB=ON  PLU=ON  POLYETHYLENE GLYCOL OR PEG
L61      20828 SEA FILE=EMBASE ABB=ON  PLU=ON  (L49 OR ?CELLULOS? OR ?DEXTRAN?
        OR ?CHITOSAN? OR ?HEPAR!N?) AND (MG OR MN OR CA OR BA OR ZN
        OR MANGANESE OR MAGNESIUM OR CALCIUM OR ZINC)
L62      188 SEA FILE=EMBASE ABB=ON  PLU=ON  L61 AND L50
L63      16 SEA FILE=EMBASE ABB=ON  PLU=ON  L62 AND DRUG(3A)(DELIVER? OR
        TARGET?)
L65      1 SEA FILE=EMBASE ABB=ON  PLU=ON  L63 AND (?COAGUL? OR ?THROMBO?)
        OR ?PLASMINOGEN?)  ) cite for embase

```

=> file hcaplus

FILE 'HCAPLUS' ENTERED AT 17:43:42 ON 28 JAN 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jan 2003 VOL 138 ISS 5
 FILE LAST UPDATED: 27 Jan 2003 (20030127/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 1141

```

L110(      91)SEA FILE=REGISTRY ABB=ON  PLU=ON  (25322-68-3/BI OR 9004-32-4/B
        I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
        83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
        OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
        OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
        26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
        I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
        50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
        OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
        111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
        I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
        26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR

```

*L110 are the
 cpds identified
 from applicants'
 work. I used it
 as a basis to
 pull out the
 various species*

51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
 OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
 OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
 OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L111(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "HEPARAN"	} <i>poly acids</i>
L112(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "HEPARIN"	
L113(8)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "CELLULOSE"	
L114(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "CHONDROITIN"	
L115(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "HYALURONIC"	
L116(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "DEXTRAN"	
L117(2)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND "CHITOSAN"	
<u>L118(</u>	15)SEA FILE=REGISTRY ABB=ON	PLU=ON	(L111 OR L112 OR L113 OR L114 OR L115 OR L116 OR L117)	
L119(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	25322-68-3	
L120(8)SEA FILE=REGISTRY ABB=ON	PLU=ON	L110 AND (CA OR ZN OR MG OR MN)/ELS <i>els = element symbol</i>	} <i>getting divalent cations</i>
L121(209)SEA FILE=REGISTRY ABB=ON	PLU=ON	"FE" AND "ION"	
L122(34)SEA FILE=REGISTRY ABB=ON	PLU=ON	L121 AND "2+"	
L123(325)SEA FILE=REGISTRY ABB=ON	PLU=ON	"CA" AND "ION"	
L124(13)SEA FILE=REGISTRY ABB=ON	PLU=ON	L123 AND "2+"	
L125(1164)SEA FILE=REGISTRY ABB=ON	PLU=ON	("ZN" OR "MG" OR "MN" OR "BA" OR "SR") AND "ION"	
L126(96)SEA FILE=REGISTRY ABB=ON	PLU=ON	L125 AND "2+"	
L127(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	STRONTIUM/CN	
L128(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	BARIUM/CN	
L129(1)SEA FILE=REGISTRY ABB=ON	PLU=ON	BERYLLIUM/CN	
L130(8)SEA FILE=REGISTRY ABB=ON	PLU=ON	"BE" AND "ION" AND "2+"	
<u>L131(</u>	157)SEA FILE=REGISTRY ABB=ON	PLU=ON	L120 OR L122 OR L124 OR (L126 OR L127 OR L128 OR L129 OR L130)	
L132(71131)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L118	<i>BIOL = Biological study</i>
L133(66401)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L119	<i>thu = therapeutic use</i>
L134(694516)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L131	<i>PKT = pharmacokinetics</i>
L135(38397)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L132(L) (BIOL OR THU OR PKT OR DMA OR PAC OR BAC)/RL	<i>DMA = Drug mechanism of action</i>
L136(15456)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L133(L) (BIOL OR THU OR PKT OR DMA OR PAC OR BAC)/RL	<i>PAC = pharmacology</i>
L137(283297)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L134(L) (BIOL OR THU OR PKT OR DMA OR PAC OR BAC)/RL	<i>BAC = Biological action</i>
L138(99)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L135 AND L136 AND L137	
L139(133270)SEA FILE=HCAPLUS ABB=ON	PLU=ON	DRUG DELIVERY SYSTEMS+NT, OLD/C T	<i>KL = Role</i>
L140(53)SEA FILE=HCAPLUS ABB=ON	PLU=ON	L138 AND L139	
<u>L141</u>	12 SEA FILE=HCAPLUS ABB=ON	PLU=ON	L140 AND GEL	<i>12 cites</i>

=> d que 1171

L142(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
 I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
 83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
 OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI

OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
 26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
 I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
 111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
 OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
 OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
 OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L143(1)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "HEPARAN"
 L144(1)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "HEPARIN"
 L145(8)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "CELLULOSE"
 L146(1)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "CHONDROITIN"
 L147(1)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "HYALURONIC"
 L148(1)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "DEXTRAN"
 L149(2)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND "CHITOSAN"
 L150(15)SEA FILE=REGISTRY ABB=ON PLU=ON (L143 OR L144 OR L145 OR
 L146 OR L147 OR L148 OR L149)
 L151(1)SEA FILE=REGISTRY ABB=ON PLU=ON 25322-68-3
 L152(8)SEA FILE=REGISTRY ABB=ON PLU=ON L142 AND (CA OR ZN OR MG OR
 MN)/ELS
 L153(209)SEA FILE=REGISTRY ABB=ON PLU=ON "FE" AND "ION"
 L154(34)SEA FILE=REGISTRY ABB=ON PLU=ON L153 AND "2+"
 L155(325)SEA FILE=REGISTRY ABB=ON PLU=ON "CA" AND "ION"
 L156(13)SEA FILE=REGISTRY ABB=ON PLU=ON L155 AND "2+"
 L157(1164)SEA FILE=REGISTRY ABB=ON PLU=ON ("ZN" OR "MG" OR "MN" OR
 "BA" OR "SR") AND "ION"
 L158(96)SEA FILE=REGISTRY ABB=ON PLU=ON L157 AND "2+"
 L159(1)SEA FILE=REGISTRY ABB=ON PLU=ON STRONTIUM/CN
 L160(1)SEA FILE=REGISTRY ABB=ON PLU=ON BARIUM/CN
 L161(1)SEA FILE=REGISTRY ABB=ON PLU=ON BERYLLIUM/CN
 L162(8)SEA FILE=REGISTRY ABB=ON PLU=ON "BE" AND "ION" AND "2+"
 L163(157)SEA FILE=REGISTRY ABB=ON PLU=ON L152 OR L154 OR L156 OR
 (L158 OR L159 OR L160 OR L161 OR L162)
 L164(71131)SEA FILE=HCAPLUS ABB=ON PLU=ON L150
 L165(66401)SEA FILE=HCAPLUS ABB=ON PLU=ON L151
 L166(694516)SEA FILE=HCAPLUS ABB=ON PLU=ON L163
 L167(38397)SEA FILE=HCAPLUS ABB=ON PLU=ON L164(L) (BIOL OR THU OR PKT OR
 DMA OR PAC OR BAC)/RL
 L168(15456)SEA FILE=HCAPLUS ABB=ON PLU=ON L165(L) (BIOL OR THU OR PKT OR
 DMA OR PAC OR BAC)/RL
 L169(283297)SEA FILE=HCAPLUS ABB=ON PLU=ON L166(L) (BIOL OR THU OR PKT OR
 DMA OR PAC OR BAC)/RL
 L170(99)SEA FILE=HCAPLUS ABB=ON PLU=ON L167 AND L168 AND L169
 L171 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L170 AND ?THROMB? / 12 cites

=> d que 1244

L203(1348)SEA FILE=HCAPLUS ABB=ON PLU=ON HEMOSTATICS+PFT/CT
 L204(1979)SEA FILE=HCAPLUS ABB=ON PLU=ON THROMBOLYTICS/CT
 L205(28185)SEA FILE=HCAPLUS ABB=ON PLU=ON BLOOD-COAGULATION FACTORS+NT,P
 FT/CT
 L206(17110)SEA FILE=HCAPLUS ABB=ON PLU=ON BLOOD COAGULATION+NT,PFT/CT
 L207(39782)SEA FILE=HCAPLUS ABB=ON PLU=ON POLYSACCHARIDES/CT
 L208(13146)SEA FILE=HCAPLUS ABB=ON PLU=ON URONIC ACIDS+NT,PFT/CT
 L209(29770)SEA FILE=HCAPLUS ABB=ON PLU=ON (L207 OR L208) (L) (BIOL OR THU
 OR DMA OR BCP OR BAC OR PKT OR PAC)/RL
 L210(64826)SEA FILE=HCAPLUS ABB=ON PLU=ON PEG OR 25322-68-3/RN
 L211(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
 I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
 83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
 OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
 OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
 26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
 I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
 111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
 OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
 OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
 OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)
 L212(8)SEA FILE=REGISTRY ABB=ON PLU=ON L211 AND (CA OR ZN OR MG OR
 MN)/ELS
 L213(209)SEA FILE=REGISTRY ABB=ON PLU=ON "FE" AND "ION"
 L214(34)SEA FILE=REGISTRY ABB=ON PLU=ON L213 AND "2+"
 L215(325)SEA FILE=REGISTRY ABB=ON PLU=ON "CA" AND "ION"
 L216(13)SEA FILE=REGISTRY ABB=ON PLU=ON L215 AND "2+"
 L217(1164)SEA FILE=REGISTRY ABB=ON PLU=ON ("ZN" OR "MG" OR "MN" OR
 "BA" OR "SR") AND "ION"
 L218(96)SEA FILE=REGISTRY ABB=ON PLU=ON L217 AND "2+"
 L219(1)SEA FILE=REGISTRY ABB=ON PLU=ON STRONTIUM/CN
 L220(1)SEA FILE=REGISTRY ABB=ON PLU=ON BARIUM/CN
 L221(1)SEA FILE=REGISTRY ABB=ON PLU=ON BERYLLIUM/CN
 L222(8)SEA FILE=REGISTRY ABB=ON PLU=ON "BE" AND "ION" AND "2+"
 L223(157)SEA FILE=REGISTRY ABB=ON PLU=ON L212 OR L214 OR L216 OR
 (L218 OR L219 OR L220 OR L221 OR L222)
 L224(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
 I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
 83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
 OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
 OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
 26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
 I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR

111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
 OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
 OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
 OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L225(1)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "HEPARAN"
 L226(1)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "HEPARIN"
 L227(8)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "CELLULOSE"
 L228(1)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "CHONDROITIN"
 L229(1)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "HYALURONIC"
 L230(1)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "DEXTRAN"
 L231(2)SEA FILE=REGISTRY ABB=ON PLU=ON L224 AND "CHITOSAN"
 L232(15)SEA FILE=REGISTRY ABB=ON PLU=ON (L225 OR L226 OR L227 OR
 L228 OR L229 OR L230 OR L231)
 L233(371)SEA FILE=REGISTRY ABB=ON PLU=ON "ALGINIC"
 L234(293)SEA FILE=REGISTRY ABB=ON PLU=ON "ALGINATE"
 L235(450)SEA FILE=REGISTRY ABB=ON PLU=ON (L233 OR L234)
 L236(694600)SEA FILE=HCAPLUS ABB=ON PLU=ON L223
 L237(283335)SEA FILE=HCAPLUS ABB=ON PLU=ON L236(L) (BIOL OR THU OR DMA OR
 BCP OR BAC OR PKT OR PAC)/RL
 L238(71147)SEA FILE=HCAPLUS ABB=ON PLU=ON L232
 L239(38408)SEA FILE=HCAPLUS ABB=ON PLU=ON L238(L) (BIOL OR THU OR DMA OR
 BCP OR BAC OR PKT OR PAC)/RL
 L240(16008)SEA FILE=HCAPLUS ABB=ON PLU=ON L235
 L241(9033)SEA FILE=HCAPLUS ABB=ON PLU=ON L240(L) (BIOL OR THU OR DMA OR
 BCP OR BAC OR PKT OR PAC)/RL
 L242(3376)SEA FILE=HCAPLUS ABB=ON PLU=ON L210 AND (L209 OR L239 OR
 L241)
 L243(137)SEA FILE=HCAPLUS ABB=ON PLU=ON L242 AND L237
 L244 9 SEA FILE=HCAPLUS ABB=ON PLU=ON L243 AND (L203 OR L204 OR
 L205 OR L206)

9 cites

=> d que 1417 ← this query display goes on through p12

L257(418531)SEA FILE=HCAPLUS ABB=ON PLU=ON CATIONS+PFT,NT/CT PFT = preferred
 L258(1348)SEA FILE=HCAPLUS ABB=ON PLU=ON HEMOSTATICS+PFT/CT forbidden
 L259(1979)SEA FILE=HCAPLUS ABB=ON PLU=ON THROMBOLYTICS/CT terms
 L260(28185)SEA FILE=HCAPLUS ABB=ON PLU=ON BLOOD-COAGULATION FACTORS+NT, P
 FT/CT
 L261(17110)SEA FILE=HCAPLUS ABB=ON PLU=ON BLOOD COAGULATION+NT, PFT/CT
 L262(39782)SEA FILE=HCAPLUS ABB=ON PLU=ON POLYSACCHARIDES/CT
 L263(13146)SEA FILE=HCAPLUS ABB=ON PLU=ON URONIC ACIDS+NT, PFT/CT
 L264(29770)SEA FILE=HCAPLUS ABB=ON PLU=ON (L262 OR L263) (L) (BIOL OR THU
 OR DMA OR BCP OR BAC OR PKT OR PAC)/RL
 L265(46803)SEA FILE=HCAPLUS ABB=ON PLU=ON L257(L) (BIOL OR THU OR DMA OR
 BCP OR BAC OR PKT OR PAC)/RL
 L266(64826)SEA FILE=HCAPLUS ABB=ON PLU=ON PEG OR 25322-68-3/RN
 L267(750)SEA FILE=HCAPLUS ABB=ON PLU=ON L264 AND L266

L268(40)SEA FILE=HCAPLUS ABB=ON PLU=ON L267 AND L257
 L269(3)SEA FILE=HCAPLUS ABB=ON PLU=ON L268 AND (L258 OR L259 OR
 L260 OR L261)
 L270(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
 I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
 83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
 OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
 OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
 26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
 I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
 111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
 OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
 OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
 OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)
 L271(8)SEA FILE=REGISTRY ABB=ON PLU=ON L270 AND (CA OR ZN OR MG OR
 MN)/ELS
 L272(209)SEA FILE=REGISTRY ABB=ON PLU=ON "FE" AND "ION"
 L273(34)SEA FILE=REGISTRY ABB=ON PLU=ON L272 AND "2+"
 L274(325)SEA FILE=REGISTRY ABB=ON PLU=ON "CA" AND "ION"
 L275(13)SEA FILE=REGISTRY ABB=ON PLU=ON L274 AND "2+"
 L276(1164)SEA FILE=REGISTRY ABB=ON PLU=ON ("ZN" OR "MG" OR "MN" OR
 "BA" OR "SR") AND "ION"
 L277(96)SEA FILE=REGISTRY ABB=ON PLU=ON L276 AND "2+"
 L278(1)SEA FILE=REGISTRY ABB=ON PLU=ON STRONTIUM/CN
 L279(1)SEA FILE=REGISTRY ABB=ON PLU=ON BARIUM/CN
 L280(1)SEA FILE=REGISTRY ABB=ON PLU=ON BERYLLIUM/CN
 L281(8)SEA FILE=REGISTRY ABB=ON PLU=ON "BE" AND "ION" AND "2+"
 L282(157)SEA FILE=REGISTRY ABB=ON PLU=ON L271 OR L273 OR L275 OR
 (L277 OR L278 OR L279 OR L280 OR L281)
 L283(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
 I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
 83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
 OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
 OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
 26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
 I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
 111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/

BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L284(1)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "HEPARAN"
L285(1)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "HEPARIN"
L286(8)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "CELLULOSE"
L287(1)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "CHONDROITIN"
L288(1)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "HYALURONIC"
L289(1)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "DEXTRAN"
L290(2)SEA FILE=REGISTRY ABB=ON PLU=ON L283 AND "CHITOSAN"
L291(15)SEA FILE=REGISTRY ABB=ON PLU=ON (L284 OR L285 OR L286 OR
L287 OR L288 OR L289 OR L290)
L292(371)SEA FILE=REGISTRY ABB=ON PLU=ON "ALGINIC"
L293(293)SEA FILE=REGISTRY ABB=ON PLU=ON "ALGINATE"
L294(450)SEA FILE=REGISTRY ABB=ON PLU=ON (L292 OR L293)
L295(694600)SEA FILE=HCAPLUS ABB=ON PLU=ON L282
L296(283335)SEA FILE=HCAPLUS ABB=ON PLU=ON L295(L) (BIOL OR THU OR DMA OR
BCP OR BAC OR PKT OR PAC)/RL
L297(71147)SEA FILE=HCAPLUS ABB=ON PLU=ON L291
L298(38408)SEA FILE=HCAPLUS ABB=ON PLU=ON L297(L) (BIOL OR THU OR DMA OR
BCP OR BAC OR PKT OR PAC)/RL
L299(16008)SEA FILE=HCAPLUS ABB=ON PLU=ON L294
L300(9033)SEA FILE=HCAPLUS ABB=ON PLU=ON L299(L) (BIOL OR THU OR DMA OR
BCP OR BAC OR PKT OR PAC)/RL
L301(3376)SEA FILE=HCAPLUS ABB=ON PLU=ON L266 AND (L264 OR L298 OR
L300)
L302(137)SEA FILE=HCAPLUS ABB=ON PLU=ON L301 AND L296
L303(9)SEA FILE=HCAPLUS ABB=ON PLU=ON L302 AND (L258 OR L259 OR
L260 OR L261)
L304(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L305(1)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "HEPARAN"

L306(1)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "HEPARIN"
 L307(8)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "CELLULOSE"
 L308(1)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "CHONDROITIN"
 L309(1)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "HYALURONIC"
 L310(1)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "DEXTRAN"
 L311(2)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND "CHITOSAN"
 L312(15)SEA FILE=REGISTRY ABB=ON PLU=ON (L305 OR L306 OR L307 OR
 L308 OR L309 OR L310 OR L311)
 L313(1)SEA FILE=REGISTRY ABB=ON PLU=ON 25322-68-3
 L314(8)SEA FILE=REGISTRY ABB=ON PLU=ON L304 AND (CA OR ZN OR MG OR
 MN)/ELS
 L315(209)SEA FILE=REGISTRY ABB=ON PLU=ON "FE" AND "ION"
 L316(34)SEA FILE=REGISTRY ABB=ON PLU=ON L315 AND "2+"
 L317(325)SEA FILE=REGISTRY ABB=ON PLU=ON "CA" AND "ION"
 L318(13)SEA FILE=REGISTRY ABB=ON PLU=ON L317 AND "2+"
 L319(1164)SEA FILE=REGISTRY ABB=ON PLU=ON ("ZN" OR "MG" OR "MN" OR
 "BA" OR "SR") AND "ION"
 L320(96)SEA FILE=REGISTRY ABB=ON PLU=ON L319 AND "2+"
 L321(1)SEA FILE=REGISTRY ABB=ON PLU=ON STRONTIUM/CN
 L322(1)SEA FILE=REGISTRY ABB=ON PLU=ON BARIUM/CN
 L323(1)SEA FILE=REGISTRY ABB=ON PLU=ON BERYLLIUM/CN
 L324(8)SEA FILE=REGISTRY ABB=ON PLU=ON "BE" AND "ION" AND "2+"
 L325(157)SEA FILE=REGISTRY ABB=ON PLU=ON L314 OR L316 OR L318 OR
 (L320 OR L321 OR L322 OR L323 OR L324)
 L326(71131)SEA FILE=HCAPLUS ABB=ON PLU=ON L312
 L327(66401)SEA FILE=HCAPLUS ABB=ON PLU=ON L313
 L328(694516)SEA FILE=HCAPLUS ABB=ON PLU=ON L325
 L329(38397)SEA FILE=HCAPLUS ABB=ON PLU=ON L326(L) (BIOL OR THU OR PKT OR
 DMA OR PAC OR BAC)/RL
 L330(15456)SEA FILE=HCAPLUS ABB=ON PLU=ON L327(L) (BIOL OR THU OR PKT OR
 DMA OR PAC OR BAC)/RL
 L331(283297)SEA FILE=HCAPLUS ABB=ON PLU=ON L328(L) (BIOL OR THU OR PKT OR
 DMA OR PAC OR BAC)/RL
 L332(99)SEA FILE=HCAPLUS ABB=ON PLU=ON L329 AND L330 AND L331
 L333(133270)SEA FILE=HCAPLUS ABB=ON PLU=ON DRUG DELIVERY SYSTEMS+NT,OLD/C
 T
 L334(53)SEA FILE=HCAPLUS ABB=ON PLU=ON L332 AND L333
 L335(12)SEA FILE=HCAPLUS ABB=ON PLU=ON L334 AND GEL
 L336(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
 I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
 83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
 OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
 OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
 26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
 I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
 111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI

OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L337(1)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "HEPARAN"
L338(1)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "HEPARIN"
L339(8)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "CELLULOSE"
L340(1)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "CHONDROITIN"
L341(1)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "HYALURONIC"
L342(1)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "DEXTRAN"
L343(2)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND "CHITOSAN"
L344(15)SEA FILE=REGISTRY ABB=ON PLU=ON (L337 OR L338 OR L339 OR
L340 OR L341 OR L342 OR L343)
L345(1)SEA FILE=REGISTRY ABB=ON PLU=ON 25322-68-3
L346(8)SEA FILE=REGISTRY ABB=ON PLU=ON L336 AND (CA OR ZN OR MG OR
MN)/ELS
L347(209)SEA FILE=REGISTRY ABB=ON PLU=ON "FE" AND "ION"
L348(34)SEA FILE=REGISTRY ABB=ON PLU=ON L347 AND "2+"
L349(325)SEA FILE=REGISTRY ABB=ON PLU=ON "CA" AND "ION"
L350(13)SEA FILE=REGISTRY ABB=ON PLU=ON L349 AND "2+"
L351(1164)SEA FILE=REGISTRY ABB=ON PLU=ON ("ZN" OR "MG" OR "MN" OR
"BA" OR "SR") AND "ION"
L352(96)SEA FILE=REGISTRY ABB=ON PLU=ON L351 AND "2+"
L353(1)SEA FILE=REGISTRY ABB=ON PLU=ON STRONTIUM/CN
L354(1)SEA FILE=REGISTRY ABB=ON PLU=ON BARIUM/CN
L355(1)SEA FILE=REGISTRY ABB=ON PLU=ON BERYLLIUM/CN
L356(8)SEA FILE=REGISTRY ABB=ON PLU=ON "BE" AND "ION" AND "2+"
L357(157)SEA FILE=REGISTRY ABB=ON PLU=ON L346 OR L348 OR L350 OR
(L352 OR L353 OR L354 OR L355 OR L356)
L358(71131)SEA FILE=HCAPLUS ABB=ON PLU=ON L344
L359(66401)SEA FILE=HCAPLUS ABB=ON PLU=ON L345
L360(694516)SEA FILE=HCAPLUS ABB=ON PLU=ON L357
L361(38397)SEA FILE=HCAPLUS ABB=ON PLU=ON L358(L) (BIOL OR THU OR PKT OR
DMA OR PAC OR BAC)/RL
L362(15456)SEA FILE=HCAPLUS ABB=ON PLU=ON L359(L) (BIOL OR THU OR PKT OR
DMA OR PAC OR BAC)/RL
L363(283297)SEA FILE=HCAPLUS ABB=ON PLU=ON L360(L) (BIOL OR THU OR PKT OR
DMA OR PAC OR BAC)/RL
L364(99)SEA FILE=HCAPLUS ABB=ON PLU=ON L361 AND L362 AND L363
L365(12)SEA FILE=HCAPLUS ABB=ON PLU=ON L364 AND ?THROMB?
L366(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B
I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI

OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L367(1)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "HEPARAN"
L368(1)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "HEPARIN"
L369(8)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "CELLULOSE"
L370(1)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "CHONDROITIN"
L371(1)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "HYALURONIC"
L372(1)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "DEXTRAN"
L373(2)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND "CHITOSAN"
L374(15)SEA FILE=REGISTRY ABB=ON PLU=ON (L367 OR L368 OR L369 OR
L370 OR L371 OR L372 OR L373)
L375(1)SEA FILE=REGISTRY ABB=ON PLU=ON 25322-68-3
L376(8)SEA FILE=REGISTRY ABB=ON PLU=ON L366 AND (CA OR ZN OR MG OR
MN)/ELS
L377(209)SEA FILE=REGISTRY ABB=ON PLU=ON "FE" AND "ION"
L378(34)SEA FILE=REGISTRY ABB=ON PLU=ON L377 AND "2+"
L379(325)SEA FILE=REGISTRY ABB=ON PLU=ON "CA" AND "ION"
L380(13)SEA FILE=REGISTRY ABB=ON PLU=ON L379 AND "2+"
L381(1164)SEA FILE=REGISTRY ABB=ON PLU=ON ("ZN" OR "MG" OR "MN" OR
"BA" OR "SR") AND "ION"
L382(96)SEA FILE=REGISTRY ABB=ON PLU=ON L381 AND "2+"
L383(1)SEA FILE=REGISTRY ABB=ON PLU=ON STRONTIUM/CN
L384(1)SEA FILE=REGISTRY ABB=ON PLU=ON BARIUM/CN
L385(1)SEA FILE=REGISTRY ABB=ON PLU=ON BERYLLIUM/CN
L386(8)SEA FILE=REGISTRY ABB=ON PLU=ON "BE" AND "ION" AND "2+"
L387(157)SEA FILE=REGISTRY ABB=ON PLU=ON L376 OR L378 OR L380 OR
(L382 OR L383 OR L384 OR L385 OR L386)
L388(71131)SEA FILE=HCAPLUS ABB=ON PLU=ON L374
L389(66401)SEA FILE=HCAPLUS ABB=ON PLU=ON L375
L390(694516)SEA FILE=HCAPLUS ABB=ON PLU=ON L387
L391(38397)SEA FILE=HCAPLUS ABB=ON PLU=ON L388(L) (BIOL OR THU OR PKT OR
DMA OR PAC OR BAC)/RL
L392(15456)SEA FILE=HCAPLUS ABB=ON PLU=ON L389(L) (BIOL OR THU OR PKT OR
DMA OR PAC OR BAC)/RL
L393(283297)SEA FILE=HCAPLUS ABB=ON PLU=ON L390(L) (BIOL OR THU OR PKT OR
DMA OR PAC OR BAC)/RL
L394(99)SEA FILE=HCAPLUS ABB=ON PLU=ON L391 AND L392 AND L393
L395(5158)SEA FILE=HCAPLUS ABB=ON PLU=ON "ANTICOAGULANTS AND ANTITHROMB
OTICS"+NT,OLD/CT
L396(4)SEA FILE=HCAPLUS ABB=ON PLU=ON L394 AND L395
L397(91)SEA FILE=HCAPLUS ABB=ON PLU=ON ("SCHWARTZ HERBERT E"/AU OR
"SCHWARTZ HERBERT EDUARD"/AU OR "SCHWARTZ H"/AU OR "SCHWARTZ H
E"/AU)
L398(27)SEA FILE=HCAPLUS ABB=ON PLU=ON BLACKMORE J?/AU
L399(15)SEA FILE=HCAPLUS ABB=ON PLU=ON CORTESE S?/AU
L400(71)SEA FILE=HCAPLUS ABB=ON PLU=ON OPPELT W?/AU
L401(196)SEA FILE=HCAPLUS ABB=ON PLU=ON (L397 OR L398 OR L399 OR
L400)
L402(3)SEA FILE=HCAPLUS ABB=ON PLU=ON L401 AND POLYACID
L403(4)SEA FILE=HCAPLUS ABB=ON PLU=ON L401 AND POLYETHER
L404(7)SEA FILE=HCAPLUS ABB=ON PLU=ON L401 AND ADHESION
L405(7)SEA FILE=HCAPLUS ABB=ON PLU=ON (L402 OR L403 OR L404)
L406(91)SEA FILE=REGISTRY ABB=ON PLU=ON (25322-68-3/BI OR 9004-32-4/B
I OR 106392-12-5/BI OR 1398-61-4/BI OR 25322-69-4/BI OR
83512-85-0/BI OR 9000-69-5/BI OR 9004-42-6/BI OR 9004-61-9/BI
OR 9005-32-7/BI OR 9005-49-6/BI OR 9007-28-7/BI OR 9044-05-7/BI
OR 25087-26-7/BI OR 26009-03-0/BI OR 26023-30-3/BI OR
26100-51-6/BI OR 26124-68-5/BI OR 26876-05-1/BI OR 28728-97-4/B

I OR 29894-36-8/BI OR 36562-70-6/BI OR 36655-86-4/BI OR
 50851-57-5/BI OR 9003-01-4/BI OR 9005-37-2/BI OR 9050-30-0/BI
 OR 101-40-6/BI OR 102-76-1/BI OR 106-69-4/BI OR 107-21-1/BI OR
 111-29-5/BI OR 114959-05-6/BI OR 139639-23-9/BI OR 14838-15-4/B
 I OR 15687-27-1/BI OR 22071-15-4/BI OR 25395-31-7/BI OR
 26446-35-5/BI OR 299-42-3/BI OR 390-28-3/BI OR 50-78-2/BI OR
 51-41-2/BI OR 51-43-4/BI OR 51-61-6/BI OR 54-49-9/BI OR
 56-81-5/BI OR 57-55-6/BI OR 7429-90-5/BI OR 7439-89-6/BI OR
 7439-95-4/BI OR 7439-96-5/BI OR 7440-47-3/BI OR 7440-66-6/BI
 OR 7440-70-2/BI OR 77-99-6/BI OR 9002-04-4/BI OR 11129-12-7/BI
 OR 124-38-9/BI OR 126-44-3/BI OR 131854-14-3/BI OR 131878-61-0/
 BI OR 1320-50-9/BI OR 14066-19-4/BI OR 14127-61-8/BI OR
 14265-44-2/BI OR 14808-79-8/BI OR 16065-83-1/BI OR 16397-91-4/B
 I OR 16887-00-6/BI OR 20074-52-6/BI OR 22537-22-0/BI OR
 22537-23-1/BI OR 23713-49-7/BI OR 338-70-5/BI OR 3812-32-6/BI
 OR 52352-27-9/BI OR 52519-63-8/BI OR 71-50-1/BI OR 71-52-3/BI
 OR 75-21-8/BI OR 7664-41-7/BI OR 7727-37-9/BI OR 9002-89-5/BI
 OR 9003-39-8/BI OR 9004-62-0/BI OR 9004-64-2/BI OR 9004-65-3/BI
 OR 9004-67-5/BI OR 9005-25-8/BI OR 9005-79-2/BI)

L407(6)SEA FILE=HCAPLUS ABB=ON PLU=ON L405 AND L406
 L408(7)SEA FILE=HCAPLUS ABB=ON PLU=ON L405 OR L407
 L409(27)SEA FILE=HCAPLUS ABB=ON PLU=ON L396 OR L365 OR L335 OR L303
 OR L269
 L410(18081)SEA FILE=HCAPLUS ABB=ON PLU=ON 139639-23-9/RN OR TPA
 L411(81)SEA FILE=HCAPLUS ABB=ON PLU=ON L410 AND L266
 L412(12)SEA FILE=HCAPLUS ABB=ON PLU=ON L411 AND L264
 L413(24)SEA FILE=HCAPLUS ABB=ON PLU=ON L411 AND (L298 OR L300)
 L414(19)SEA FILE=HCAPLUS ABB=ON PLU=ON (L412 OR L413) AND (L296 OR
 L265 OR HEPARIN OR 9005-49-6/RN OR ANTITHROMB? OR ANTI-THROMB?
 OR ANTI(W)THROMB?)
 L415(17)SEA FILE=HCAPLUS ABB=ON PLU=ON L414 NOT L408
 L416(13)SEA FILE=HCAPLUS ABB=ON PLU=ON L415 NOT L409
 L417 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L416 AND (ALKALI OR CHELAT?
 OR L257 OR L295)

registr # for
TPA

2 cites

=> s 1141 or 1171 or 1244 or 1417

L421 26 L141 OR L171 OR L244 OR L417 26 cites total for HCAPLUS

=> (s 1421 AND (GEL OR HYDROGEL OR (SUSTAINED RELEASE MICROSPHERES)))

weeding the
L421 cites

413690 GEL
 81606 GELS
 445873 GEL
 (GEL OR GELS)
 11590 HYDROGEL
 9520 HYDROGELS
 14272 HYDROGEL
 (HYDROGEL OR HYDROGELS)
 57307 SUSTAINED
 387452 RELEASE
 19344 RELEASES
 398758 RELEASE
 (RELEASE OR RELEASES)
 17715 MICROSPHERES

95 SUSTAINED RELEASE MICROSPHERES
(SUSTAINED(W) RELEASE(W) MICROSPHERES)

15 cites
for WCAPLUS

L422 15 L421 AND (GEL OR HYDROGEL OR (SUSTAINED RELEASE MICROSPHERES))

=> file wpix

FILE 'WPIX' ENTERED AT 17:46:09 ON 28 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 24 JAN 2003 <20030124/UP>
MOST RECENT DERWENT UPDATE: 200306 <200306/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> DUE TO TECHNICAL ISSUES THE SDIS FOR UPDATES 200302-200304
BASED ON ENTRY DATE (ED) MAY CONTAIN DOCUMENTS PREVIOUSLY
DISTRIBUTED. IF YOU ENCOUNTER ANY SURPLUS DOCUMENTS OF THIS
KIND, PLEASE CONTACT OUR HELPDESKS. UNJUSTIFIED CHARGES
INCURRED WILL BE REVOKED OF COURSE.
WE APOLOGIZE FOR ANY INCONVENIENCE CAUSED. <<<

>>> SLART (Simultaneous Left and Right Truncation) is now
available in the /ABEX field. An additional search field
/BIX is also provided which comprises both /BI and /ABEX <<<

>>> PATENT IMAGES AVAILABLE FOR PRINT AND DISPLAY <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE <http://www.derwent.com/dwpi/updates/dwpicov/index.html> <<<

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
http://www.derwent.com/userguides/dwpi_guide.html <<<

=> d que 186

L77 20350 SEA FILE=WPIX ABB=ON PLU=ON (POLYSACCHARID? OR ?CELLULOS? OR
?DEXTRAN? OR ?CHITOSAN? OR ?HEPAR!N?) AND (MG OR MN OR CA OR
BA OR ZN OR MANGANESE OR MAGNESIUM OR CALCIUM OR ZINC)
L78 37636 SEA FILE=WPIX ABB=ON PLU=ON POLYETHYLENE GLYCOL OR PEG
L79 1044 SEA FILE=WPIX ABB=ON PLU=ON L77 AND L78
L81 1044 SEA FILE=WPIX ABB=ON PLU=ON L78 AND L79
L82 146 SEA FILE=WPIX ABB=ON PLU=ON L81 AND GEL
L83 117 SEA FILE=WPIX ABB=ON PLU=ON L81 AND (CROSSLINK? OR CROSS(W) LI
NK? OR CROSS-LINK?)
L84 30 SEA FILE=WPIX ABB=ON PLU=ON L82 AND L83
L85 3 SEA FILE=WPIX ABB=ON PLU=ON L84 AND CATION
L86 1 SEA FILE=WPIX ABB=ON PLU=ON L85 AND PARTICLE/TI

1 citation

=> d que 197

L77 20350 SEA FILE=WPIX ABB=ON PLU=ON (POLYSACCHARID? OR ?CELLULOS? OR
?DEXTRAN? OR ?CHITOSAN? OR ?HEPAR!N?) AND (MG OR MN OR CA OR
BA OR ZN OR MANGANESE OR MAGNESIUM OR CALCIUM OR ZINC)
L78 37636 SEA FILE=WPIX ABB=ON PLU=ON POLYETHYLENE GLYCOL OR PEG
L79 1044 SEA FILE=WPIX ABB=ON PLU=ON L77 AND L78
L89 84 SEA FILE=WPIX ABB=ON PLU=ON L79 AND (?COAGUL? OR ?THROMBO?

B = Biotech, Food, deter-
gents, water treatment
DC = Derwent code

OWENS 09/472,110

OR ?PLASMINOGEN? OR FIBRIN?)
L90 13 SEA FILE=WPIX ABB=ON PLU=ON L89 AND (CATION OR CATIONIC OR
Divalent? OR ALKALINE EARTH)
L91 12 SEA FILE=WPIX ABB=ON PLU=ON L90 AND B/DC
L97 6 SEA FILE=WPIX ABB=ON PLU=ON L91 AND (INORGANIC/TI OR *6 citations*
AMYLOID/TI OR GEL OR CROSSLINK? OR CROSS(W)LINK? OR CROSS-LINK?

=> s 186 or 197

L423 7 L86 OR L97 7 cites total from WPIX (Derwent)

=> dup rem 1420 165 1422 1423 removing duplicate citations
FILE 'MEDLINE' ENTERED AT 17:46:50 ON 28 JAN 2003

FILE 'EMBASE' ENTERED AT 17:46:50 ON 28 JAN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 17:46:50 ON 28 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 17:46:50 ON 28 JAN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
PROCESSING COMPLETED FOR L420
PROCESSING COMPLETED FOR L65
PROCESSING COMPLETED FOR L422
PROCESSING COMPLETED FOR L423

L424 22 DUP REM L420 L65 L422 L423 (3 DUPLICATES REMOVED) 22 citations
total

=> bib abs hitstr 1-22; file home

L424 ANSWER 1 OF 22 HCAPLUS/ COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:408783 HCAPLUS
DOCUMENT NUMBER: 137:2412
TITLE: Petunia hybrida gene Shooting encoding cytokinin
biosynthesis enzyme tRNA-IPT and uses in plant growth
regulation and cosmetic preparations
INVENTOR(S): Meyer, Peter; Zubko, Elena
PATENT ASSIGNEE(S): University of Leeds, UK
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042440	A2	20020530	WO 2001-GB5175	20011126
WO 2002042440	A3	20021017		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2002023877 A5 20020603 AU 2002-23877 20011126
 PRIORITY APPLN. INFO.: GB 2000-28827 A 20001125
 GB 2001-971 A 20010113
 GB 2001-23970 A 20011005
 WO 2001-GB5175 W 20011126

AB The present invention provides a naturally occurring plant gene encoding a cytokinin (CK) biosynthesis enzyme. In an activation tagging expt. a Petunia hybrida line was identified that showed CK-specific effects including control of cellular processes such as plant growth, enhanced shooting, reduced apical dominance and delayed senescence and flowering. This phenotype correlated with the enhanced expression of a gene we labeled Shooting (Sho). The petunia "Shooting" gene, which encodes a homolog to Arabidopsis thaliana transfer ribonucleate-isopentenyltransferase (tRNA-IPT)-like proteins, also causes CK-specific effects when expressed in other plant species. In contrast to the ipt gene from Agrobacterium, which primarily increases CK zeatin levels, Shooting expression in petunia and tobacco esp. enhances the levels of certain N6-(.DELTA.2-isopentenyl) adenosine (2iP) derivs. The present invention provides Petunia Shooting gene and protein sequences and uses therefor and control thereof in the prodn. of plants and/or plant cells that are capable of exhibiting a variety of advantageous characteristics assocd. with CK regulated processes. A further aspect of the invention there is provided use as a cosmetic to reduce the signs of skin ageing the plant ext. which includes a transcriptionally activated/activatable form of the Shooting.

IT 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 9004-61-9, Hyaluronic acid 9007-28-7, Chondroitin sulfate 25322-68-3, PEG 75

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (cosmetic prepn. further comprising; petunia gene Shooting encoding CK biosynthesis enzyme tRNA-IPT and plant growth regulation and cosmetic preps.)

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 7440-70-2 HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 9004-61-9 HCAPLUS

CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9007-28-7 HCAPLUS

CN Chondroitin, hydrogen sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 9007-27-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L424 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:275770 HCAPLUS

DOCUMENT NUMBER: 136:299729

TITLE: Biodegradable controlled release microparticles containing amylopectin-based starch of reduced molecular weight

INVENTOR(S): Joensson, Monica; Gustavsson, Nils Ove; Laakso, Timo; Reslow, Mats

PATENT ASSIGNEE(S): Bioglan AB, Swed.

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028370	A1	20020411	WO 2001-SE2164	20011005
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SE 2000003615	A	20020407	SE 2000-3615	20001006
SE 517421	C2	20020604		
AU 2001094458	A5	20020415	AU 2001-94458	20011005
US 2002044976	A1	20020418	US 2001-970793	20011005
US 2002098203	A1	20020725	US 2002-970794	20020110

PRIORITY APPLN. INFO.:

SE 2000-3615 A 20001006
 US 2001-260455P P 20010108
 WO 2001-SE2164 W 20011005

AB A process for producing parenterally administrable microparticles, in which an at least 20% by wt. aq. soln. of purified amylopectin-based starch of reduced mol. wt. is prepd., the soln. is combined with a biol. active substance, an emulsion of starch droplets is formed in an outer phase of polymer soln., the starch droplets are made to gel, and the gelled starch particles are dried. A release-controlling shell is optionally also applied to the particles. Microparticles which essentially consist of the starch, have an amino acid content of <50 .mu.g and have no covalent chem. crosslinking. Thus, starch microspheres contg. BSA were produced from highly branched starch with av. mol. wt. of 1930 kDA. The starch soln. was mixed with PEG and the mixt. was administered s.c. and i.m. to rats. The microspheres were biodegraded rapidly within 1 wk, and the tissue is rapidly normalized.

IT 7440-66-6D, Zinc, human growth hormone complexes 9001-24-5
 , Blood coagulation factor V 9001-28-9, Blood coagulation factor IX 9001-29-0, Blood coagulation factor X 9001-30-3, Blood coagulation factor XII 9013-56-3, Blood coagulation factor XIII 25322-68-3, Polyethylene glycol 113189-02-9, Blood coagulation factor VIII

RL: THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(biodegradable controlled release microparticles contg. reduced mol.-wt amylopectin-based starch)

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 9001-24-5 HCAPLUS

CN Blood-coagulation factor V (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9001-28-9 HCAPLUS

CN Blood-coagulation factor IX (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9001-29-0 HCAPLUS

CN Blood-coagulation factor X (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9001-30-3 HCAPLUS

CN Blood-coagulation factor XII (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 9013-56-3 HCAPLUS

CN Blood-coagulation factor XIII (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 113189-02-9 HCAPLUS

CN Blood-coagulation factor VIII, procoagulant (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:213707 HCAPLUS

DOCUMENT NUMBER: 136:252489

TITLE: Sustained-release polymer blend for pharmaceutical applications

INVENTOR(S): Guo, Jian Hwa; Skinner, George William

PATENT ASSIGNEE(S): Hercules Incorporated, USA

SOURCE: U.S., 9 pp., Cont.-in-part of U.S. 6,210,710.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6358525	B1	20020319	US 1999-343425	19990630
US 6210710	B1	20010403	US 1997-847842	19970428
NO 9801893	A	19981029	NO 1998-1893	19980427

PRIORITY APPLN. INFO.: US 1997-847842 A2 19970428

AB A pharmaceutical compn. has a blend of at least first and second components and a medicament in a sufficient amt. to be therapeutic where the first component is hydroxypropylcellulose and the second component is at least one other polymer selected from the group consisting of methylcellulose, ethylhydroxyethylcellulose, hydroxyethylmethylcellulose, hydrophobically modified hydroxyethylcellulose, hydrophobically modified ethylhydroxyethylcellulose, carboxymethylhydroxyethylcellulose, carboxymethyl hydrophobically modified hydroxyethylcellulose, guar, pectin, carrageenan, agar, algin, gellan gum, acacia, starch and modified starches, co-polymers of carboxyvinyl monomers, co-polymers of acrylate or methacrylate monomers, mono- and co-polymers of oxyethylene and oxypropylene and mixts. thereof and a medicament in a sufficient amt. to be therapeutic, with the proviso that low-substituted hydroxypropylcellulose is excluded from said first and second components. The medicament can be a variety of drugs or nutritional supplements. The pharmaceutical compn. releases the medicament for a prolonged or sustained period of time and can be formulated into many dosage forms. A tablet contained Klucel HXF 37.5, Aqualon CMC 7L2P 112.5, phenylpropanolamine hydrochloride 75, avicel PH-101 162, povidone 12, reduced granulation 299, Avicel PH-102 96, magnesium starate 5%.

IT 9004-64-2, Hydroxypropylcellulose 9004-67-5,
Methylcellulose 14127-61-8, Calcium ion, biological studies
22537-22-0, Magnesium ion, biological studies 25322-68-3
, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(sustained-release polymer blend for pharmaceutical applications)

RN 9004-64-2 HCAPLUS
 CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
 CMF C3 H8 O2



RN 9004-67-5 HCAPLUS
 CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
 CMF C H4 O



RN 14127-61-8 HCAPLUS
 CN Calcium, ion (Ca²⁺) (8CI, 9CI) (CA INDEX NAME)



RN 22537-22-0 HCAPLUS
 CN Magnesium, ion (Mg²⁺) (8CI, 9CI) (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)

INVENTOR(S): oxides
Cortese, Stephanie M.; Schwartz, Herbert E.; Oppelt, William G.
PATENT ASSIGNEE(S): Fziomed, Inc., USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082937	A1	20011108	WO 2001-US13520	20010426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002010150	A1	20020124	US 2001-843588	20010426
US 2002028181	A1	20020307	US 2001-843194	20010426
PRIORITY APPLN. INFO.:			US 2000-200457P	P 20000428
			US 2000-200637P	P 20000428
			US 1999-472110	A 19991227

AB The present invention relates to improved methods for making and using hemostatic, bioadhesive, bioresorbable, anti-adhesion compns. made of intermacromol. complexes of carboxyl-contg. polysaccharides, polyether, polyacids, polyalkylene oxides, and optionally including multivalent cations and/or polycations and/or hemostatic agents. The polymers can be assocd. with each other, and are then either dried into membranes or sponges, or are used as fluids, **gels**, or foams. Hemostatic, bioresorbable, bioadhesive, anti-adhesion compns. are useful in surgery to prevent bleeding and the formation and reformation of post-surgical adhesions. The compns. are designed to breakdown in-vivo, and thus be removed from the body. The hemostatic, anti-adhesion, bioadhesive, bioresorptive, **antithrombogenic** and/or phys. properties of such compns. can be varied as needed by carefully adjusting the pH, solids content cation content of the polymer casting solns., polyacid compn., the polyalkylene oxide compn., or by adding hemostatic agents. Hemostatic membranes, **gels** and/or foams can be used concurrently. Hemostatic, antiadhesion compns. may also be used to lubricate tissues and/or medical instruments, and/or deliver drugs to the surgical site and release them locally. CMC/PEO membranes, esp. the 50/50 CMC/PEO membrane, is highly anti-**thrombogenic**, based on the redn. in the no. of adherent platelets and the extent of platelet activation on these surfaces. Thus, increasing the amt. of PEO in membranes increases their **antithrombogenic** properties.

IT 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 9004-32-4, Carboxymethyl cellulose 9004-42-6, Carboxyethyl cellulose 9004-61-9, Hyaluronic acid 9005-32-7, Alginic acid 9005-37-2, Propylene glycol Alginate 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9044-05-7, Carboxymethyl dextran 9050-30-0, Heparan sulfate 25322-68-3, Polyethylene glycol 83512-85-0,

Carboxymethyl chitosan

RL: THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(hemostatic compns. of polyacids and polyalkylene oxides)

RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7439-96-5 HCAPLUS

CN Manganese (8CI, 9CI) (CA INDEX NAME)

Mn

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 7440-70-2 HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 9004-32-4 HCAPLUS

CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1

CMF C2 H4 O3



RN 9004-42-6 HCAPLUS

CN Cellulose, 2-carboxyethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 503-66-2
CMF C3 H6 O3

HO-CH₂-CH₂-CO₂H

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-32-7 HCAPLUS
CN Alginic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-37-2 HCAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2

OH
|
H₃C-CH-CH₂-OH

RN 9005-49-6 HCAPLUS
CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9007-28-7 HCAPLUS
CN Chondroitin, hydrogen sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 9007-27-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 9044-05-7 HCAPLUS
CN Dextran, carboxymethyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-54-0
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9050-30-0 HCAPLUS
CN Heparan, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 70226-44-7
CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)

NAME)



RN 83512-85-0 HCAPLUS

CN Chitosan, N-(carboxymethyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 2

ACCESSION NUMBER: 2001:816395 HCAPLUS

DOCUMENT NUMBER: 135:362559

TITLE: Polyacid/polyalkylene oxide foams and gels
for drug deliveryINVENTOR(S): Miller, Mark E.; Cortese, Stephanie M.; Schwartz,
Herbert E.; Oppelt, William G.

PATENT ASSIGNEE(S): Fziomed, Inc., USA

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001082863	A2	20011108	WO 2001-US13505	20010426
WO 2001082863	A3	20020221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001059177	A5	20011112	AU 2001-59177	20010426
US 2002010150	A1	20020124	US 2001-843588	20010426
US 2002028181	A1	20020307	US 2001-843194	20010426
PRIORITY APPLN. INFO.:			US 2000-200457P	P 20000428
			US 2000-200637P	P 20000428
			US 1999-472110	A 19991227
			WO 2001-US13505	W 20010426

AB The present invention relates to improved methods for delivering bioadhesive, bioresorbable, anti-adhesion compns. Antiadhesion compns. can be made of intermacromol. complexes of carboxyl-contg. polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and/or polycations. The polymers are assocd. with each other, and are then used as fluids, gels or foams. By providing a product bag, the compns. can be delivered as gels or as sprays. By dissolving propellant gases in the compns., the materials can be delivered as foams, which have decreased d., and therefore can adhere to surfaces that previously have been difficult to coat with antiadhesion gels

. Delivery systems can also provide mechanisms for expelling more product, and for directing the flow of materials leaving the delivery system. Bioresorbable, bioadhesive, anti-adhesion, and/or hemostatic compns. are useful in surgery to prevent the formation and reformation of post-surgical adhesions. The biol. and phys. properties of such compns. can be varied as needed by carefully adjusting the pH and/or cation content of the polymer casting solns., polyacid compn., the polyalkylene oxide compn., or by selecting the solids content of the compn. Antiadhesion compns. may also be used to lubricate tissues and/or medical instruments, and/or deliver drugs to the surgical site and release them locally. An antiadhesion compn. comprising a **gel** was loaded into a CCL ABS canister with a liner. The compn. comprised 2.2% total solids with a ratio of CMC to **PEG** of 97.5:2.5, and included sufficient Ca to provide a 60% ionically assocd. complex. Portions of the compn. were sterilized in an autoclave at a temp. of 122.degree. for 35 min.

IT 7439-95-4, Magnesium, biological studies 7439-96-5, Manganese, biological studies 7440-66-6, Zinc, biological studies 7440-70-2, Calcium, biological studies 9004-32-4, Carboxymethyl cellulose 9004-42-6, Carboxyethyl cellulose 9004-61-9, Hyaluronic acid 9005-32-7, Alginic acid 9005-37-2, Propylene glycol Alginate 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9044-05-7, Carboxymethyl dextran 9050-30-0, Heparan sulfate 25322-68-3, Polyethylene glycol 83512-85-0, Carboxymethyl chitosan

RL: **THU (Therapeutic use); BIOL (Biological study);**

USES (Uses)

(polyacid/polyalkylene oxide foams and **gels** for drug delivery)

RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7439-96-5 HCAPLUS

CN Manganese (8CI, 9CI) (CA INDEX NAME)

Mn

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 7440-70-2 HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 9004-32-4 HCAPLUS

CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9004-42-6 HCAPLUS
CN Cellulose, 2-carboxyethyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 503-66-2
CMF C3 H6 O3



RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-32-7 HCAPLUS
CN Alginic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-37-2 HCAPLUS
CN Alginic acid, ester with 1,2-propanediol (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9005-32-7
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9005-49-6 HCAPLUS
CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9007-28-7 HCAPLUS
CN Chondroitin, hydrogen sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 9007-27-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
CMF H2 O4 S



RN 9044-05-7 HCAPLUS
CN Dextran, carboxymethyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-54-0
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6458387 B1 20021001 US 1999-420361 19991018
 EP 1223917 A1 20020724 EP 2000-973477 20001012

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: US 1999-420361 A 19991018
 WO 2000-US28200 W 20001012

AB A microsphere compn. for sustained release of therapeutic or diagnostic agents comprises (1) a carrier protein, (2) a water-sol. polymer, (3) a polyanionic polysaccharide as a first complexing agent, and (4) a divalent metal cation (Ca and Mg) as a second complexing agent. The microspheres have a smooth surface that includes a plurality of channel openings that are < 1000 .ANG. in diam. Various drugs were encapsulated into microspheres. For example, microspheres contg. leuprolide acetate were prepd. using human serum albumin (HSA), dextran sulfate, polyethylene glycol, and polyvinylpyrrolidone. The microspheres were composed of approx. 10% leuprolide acetate, 50% human serum albumin, 20% dextran sulfate and 20% polyethylene glycol/polyvinylpyrrolidone. Similar particles were prepd. which also included zinc sulfate or caprylic acid, both of which retarded the release of protein and peptide from the microspheres. Also, rifampicin-contg. HSA microspheres were prepd. with HSA incorporation of 74% and rifampicin incorporation into the particles of > 6.8%. The av. size of the particles was detd. to be 68 nm in diam.

IT 685-73-4, Galacturonic acid 7439-95-4, Magnesium, biological studies 7440-70-2, Calcium, biological studies 9004-32-4, Carboxymethyl cellulose 9004-61-9, Hyaluronic acid 9004-67-5, Methyl cellulose 9005-32-7, Alginic acid 9005-49-6, Heparin, biological studies 9007-28-7, Chondroitin sulfate 9050-30-0, Heparan sulfate 25322-68-3, Polyethylene oxide 139639-23-9, Tissue plasminogen activator


RL: THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)

(sustained-release microspheres based on
 carrier protein, water sol. polymer and complexing agents)

RN 685-73-4 HCAPLUS

CN D-Galacturonic acid (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-70-2 HCAPLUS
CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 9004-32-4 HCAPLUS
CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9004-67-5 HCAPLUS
CN Cellulose, methyl ether (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 67-56-1
CMF C H4 O



RN 9005-32-7 HCAPLUS
CN Alginic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-49-6 HCAPLUS
CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9007-28-7 HCAPLUS

CN Chondroitin, hydrogen sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 9007-27-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 9050-30-0 HCAPLUS

CN Heparan, sulfate (9CI) (CA INDEX NAME)

CM 1

CRN 70226-44-7

CMF Unspecified


CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2


CRN 7664-93-9

CMF H2 O4 S



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 139639-23-9 HCAPLUS
CN Plasminogen activator, tissue-type (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:886568 HCAPLUS

DOCUMENT NUMBER: 136:42803

TITLE: Conjugate addition reactions for the controlled
delivery of pharmaceutically active compounds

INVENTOR(S): Hubbel, Jeffrey A.; Elbert, Donald; Schoenmakers,
Ronald

PATENT ASSIGNEE(S): Eidgenossische Technische Hochschule Zurich, Switz.;
Universitat Zurich

SOURCE: PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092584	A1	20011206	WO 2001-US18101	20010604
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2000-586937 A2 20000602

OTHER SOURCE(S): MARPAT 136:42803

AB The invention features polymeric biomaterials formed by nucleophilic addn. reactions to conjugated unsatd. groups. These biomaterials may be used for medical treatments.

IT 7440-66-6, Zinc, biological studies 9005-49-6, Heparin, biological studies

RL: BSU (Biological study, unclassified); **BIOL (Biological study)**
(-binding agents; conjugate addn. reactions for the controlled delivery of pharmaceutically active compds.)

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 9005-49-6 HCAPLUS

CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 25322-68-3, Polyethylene glycol

RL: DEV (Device component use); **THU (Therapeutic use); BIOL (Biological study); USES (Uses)**

(conjugate addn. reactions for the controlled delivery of

RN 9050-30-0 HCAPLUS
 CN Heparan, sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 70226-44-7
 CMF Unspecified
 CCI MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
 CMF H2 O4 S



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



RN 83512-85-0 HCAPLUS
 CN Chitosan, N-(carboxymethyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L424 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 3

ACCESSION NUMBER: 2001:300486 HCAPLUS

DOCUMENT NUMBER: 134:331616

TITLE: **Sustained release**

microspheres based on a carrier protein, a water soluble polymer and complexing agents

INVENTOR(S): Scott, Terrence L.; Brown, Larry R.; Riske, Frank J.; Blizzard, Charles D.; Rashba-Step, Julia

PATENT ASSIGNEE(S): Epic Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028524	A1	20010426	WO 2000-US28200	20001012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 4 OF 22 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
 ACCESSION NUMBER: 2002203779 EMBASE
 TITLE: Delivery of LMW **heparin** via surface coated **chitosan/peg**-alginate microspheres prevents **thrombosis**.
 AUTHOR: Chandy T.; Rao G.H.R.; Wilson R.F.; Das G.S.
 CORPORATE SOURCE: T. Chandy, Departments of Cardiology, University of Minnesota, Mayo Mail Code 508, 420 Delaware St. SE, Minneapolis, MN 55455, United States. chand025@tc.umn.edu
 SOURCE: Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents, (2002) 9/2 (87-96).
 Refs: 34
 ISSN: 1071-7544 CODEN: DDELEB
 COUNTRY: United States
 DOCUMENT TYPE: Journal; Article
 FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery
 030 Pharmacology
 037 Drug Literature Index
 039 Pharmacy
 LANGUAGE: English
 SUMMARY LANGUAGE: English

AB **Heparin** remains the gold-standard inhibitor of the process involved in the vascular response to injury. Continued **anticoagulation** is achieved by subcutaneous administration of low-molecular-weight **heparin** (LMW Hep) or with an orally active **anticoagulant** such as warfarin. An oral **heparin** would avoid the inconvenience of subcutaneous injections and adverse events associated with warfarin. A mild **chitosan/PEG/calcium** alginate microencapsulation process, as applied to encapsulation of biological macromolecules such as **heparin** and LMW Hep was investigated. **Heparin** and LMW Hep entrapped alginate beads were further surface/enteric coated with **chitosan** and **cellulose** acetate phthalate (CAP) via carbodiimide (EDC) functionalities. It was observed that approximately 70% of the content is being released into Tris-HCl buffer, pH 7.4 within the initial 6 hours and no significant release of LMW Hep was observed from enteric coated microspheres (12%) during treatment with 0.1 M HCl, pH 1.0 for 4 hours. But acid treated capsules had released almost all the entrapped LMW Hep into Tris-HCl, pH 7.4 media within 6 hours. From scanning electron microscopic and swelling studies, it appeared that the surface coatings (via **chitosan** and CAP) had modified the alginate microspheres and subsequently the drug release. The released **heparin** and LMW Hep had shown their **anticoagulant** functions. These results established the feasibility of modifying the formulation in order to obtain the desired controlled release of bioactive agent (LMW Hep), for a convenient pH dependent delivery system.

L424 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
 ACCESSION NUMBER: 2001:816464 HCAPLUS
 DOCUMENT NUMBER: 135:362573
 TITLE: Hemostatic compositions of polyacids and polyalkylene

pharmaceutically active compds.)
 RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:265231 HCAPLUS

DOCUMENT NUMBER: 134:285589

TITLE: Gel-forming compositions containing polysaccharides and alkyl sulfate salts

INVENTOR(S): Browne, L. Daniel; Dake, Michael D.; Waugh, Jacob

PATENT ASSIGNEE(S): Essentia Biosystems, Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024775	A1	20010412	WO 2000-US27186	20001002
WO 2001024775	C2	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001010728	A5	20010510	AU 2001-10728	20001002
PRIORITY APPLN. INFO.: US 1999-157365P P 19991001				
US 2000-675566 A 20000929				
WO 2000-US27186 W 20001002				


AB Aq. gel-forming compns. contain a biocompatible hydroxyalkyl or carboxyalkyl polysaccharide deriv., an alkali metal alkyl sulfate having 6-20 C atoms, a therapeutic or diagnostic agent, and optionally, a biocompatible inorg. salt. The gel-forming compns. show an increase in viscosity upon application of shear (i.e., shear-thickening) sufficient to form a gel. The resulting gel typically relaxes over time returning to a low viscosity compn. in the absence of shear. The disclosed gel-forming compns. are useful for administering a therapeutic or diagnostic agent to a patient in need of treatment or diagnosis; and for biomedical interventional procedures, such as catheter-based vascular embolization, angiogenesis, or other tissue specific applications. A stock soln. of hydroxypropyl cellulose was prepd. by adding Klucel HFNF (hydroxypropyl cellulose) to 200 mL normal saline. Similarly, a stock soln. of PEG was prepd. by dissolving PEG in normal saline and

stirring for 15 min as above prior to use in the gel-forming compn. A soln. of sodium dodecyl sulfate in water was prepd. and the 3 solns. were mixed and added to fluorescein isothiocyanate and the mixt. formed a gel. The viscosity of the gel was 3,000,000 cP.

IT 9004-32-4, Carboxymethyl cellulose sodium salt 9004-64-2
 , Hydroxypropyl cellulose 9005-49-6, Heparin,
 biological studies 139639-23-9, Tissue plasminogen activator
 RL: THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (gel-forming compns. contain polysaccharides and alkyl
 sulfate salts)
 RN 9004-32-4 HCAPLUS
 CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)
 CM 1
 CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2
 CRN 79-14-1
 CMF C2 H4 O3



RN 9004-64-2 HCAPLUS
 CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)
 CM 1
 CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2
 CRN 57-55-6
 CMF C3 H8 O2



RN 9005-49-6 HCAPLUS
 CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

EP 1200134 A1

EP 1999-935897 19990722

WO 1999-US16804 19990722

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9951275	A Based on	WO 200105438
EP 1200134	A1 Based on	WO 200105438

PRIORITY APPLN. INFO: US 1999-356178 19990716

AN 2001-123203 [13] WPIX

AB WO 200105438 A UPAB: 20020130

NOVELTY - A targeted ultrasound contrast agent comprising a carrier and a particle (I) is new.

DETAILED DESCRIPTION - A Targeted ultrasound contrast agent comprising a carrier and a particle of formula (I) is new.

P = porous particle of an inorganic material with an average particle diameter of 0.05-500 microns and containing an entrapped gas or liquid;

L = absent or is a linker; and

T = targeting ligand.

An INDEPENDENT CLAIM is included for a method of ultrasound imaging in a mammal involving administration of a targeted ultrasound contrast agent comprising a carrier and a particle of formula (I) which alters the ultrasound echogenicity of the target to be imaged.

USE - The targeted contrast agents are useful for ultrasound imaging in diagnostic procedures e.g. for oncologic, gastrointestinal and cardiovascular uses e.g. in the detection and diagnosis of ischemia.

ADVANTAGE - The inorganic particles of the invention have good mechanical stability and rigidity, which are important attributes lacking in other materials used as ultrasound contrast agents such as sonicated albumin microspheres and perfluorocarbon emulsions. They can readily be prepared and fabricated into a variety of shapes and sizes and extents of porosity, in order to obtain the most desirable contrast effects. Also, inorganic porous particles can be prepared with a range of different solubilities in an aqueous solution, such as body fluid.

Dwg.0/0

L424 ANSWER 12 OF 22 WPIX (C) 2003 THOMSON DERWENT

ACCESSION NUMBER: 2001-112499 [12] WPIX

CROSS REFERENCE: 2001-091751 [10]

DOC. NO. CPI: C2001-033517

TITLE: Method for controlling the flux of penetrants across an adaptable semi-permeable barrier is useful for administering an agent to a mammalian body or a plant and for generating an immune response by vaccinating the mammal.

DERWENT CLASS: A18 A28 A96 B05 B07 D16 D22

INVENTOR(S): CEVC, G; RICHARDSEN, H; WEILAND-WAIBEL, A;
WEILAND-WEIBEL, A

PATENT ASSIGNEE(S): (IDEA-N) IDEA AG

COUNTRY COUNT: 95

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001001963	A1	20010111	(200112)*	EN	110
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM					

DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW
 AU 2000061557 A 20010122 (200125)
 BR 2000012178 A 20020312 (200226)
 EP 1189598 A1 20020327 (200229) EN
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI
 CZ 2002000038 A3 20020515 (200241)
 CN 1359288 A 20020717 (200268)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001001963	A1	WO 2000-EP6367	20000705
AU 2000061557	A	AU 2000-61557	20000705
BR 2000012178	A	BR 2000-12178	20000705
		WO 2000-EP6367	20000705
EP 1189598	A1	EP 2000-947939	20000705
		WO 2000-EP6367	20000705
CZ 2002000038	A3	WO 2000-EP6367	20000705
		CZ 2002-38	20000705
CN 1359288	A	CN 2000-809916	20000705

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000061557	A Based on	WO 200101963
BR 2000012178	A Based on	WO 200101963
EP 1189598	A1 Based on	WO 200101963
CZ 2002000038	A3 Based on	WO 200101963

PRIORITY APPLN. INFO: WO 1999-EP4659 19990705

AN 2001-112499 [12] WPIX

CR 2001-091751 [10]

AB WO 200101963 A UPAB: 20021022

NOVELTY - A method for controlling the flux of penetrants across an adaptable semi-permeable porous barrier is new.

DETAILED DESCRIPTION - A method for controlling the flux of penetrants across an adaptable semi-permeable membrane comprises suspending the penetrants in a polar liquid in the form of fluid droplets surrounded by a membrane-like coating comprising at least two kinds of amphiphilic substances with a tendency to aggregate, selecting a dose of the penetrants to control the flux of the penetrants across the barrier and applying the selected dose of the formulation onto the area of the barrier. The amphiphilic substances differ by a factor of at least 10 in solubility in the polar liquid and the homo-aggregates of the more soluble substance and hetero-aggregates have a preferred average diameter smaller than the diameter of the homo-aggregates of the less soluble substance. The more soluble substance tends to solubilize the droplet and comprises up to 99% of the solubilizing concentration or saturating concentration in the unstabilized droplet. The presence of the more soluble substance lowers the average elastic energy of the coating by at least 5 times preferably more than 10 times the average elastic energy of red blood cells or of phospholipid bilayers with fluid aliphatic chains. The penetrants are able to transport agents through the pores of the barrier or enable agent permeation through the pores after the penetrants have entered the pores.

or more bilayer-forming diacyl membrane lipids. The compns. are characterized by the presence of an effective amt. of the monoacyl component and a lipophilic component dissolved or dispersed in a hydrophilic medium in an amt. effective to convert the compn. into a liq., gel or semi-solid which has the property of yielding dispersed lipid aggregates upon contact or further diln. with an aq. medium. Particular liq. pharmaceutical compns. comprise: (a) a mixt. of membrane lipids which comprises a micelle-forming lipid and preferably a bilayer-forming lipid; (b) a lipophilic component; (c) at least one hydrophilic medium to mobilize the lipids; and optionally (d) a biol. active compd. Other compns. comprise water in an amt. which is effective to hydrate the lipid mixt., and a biol. active compd. Enzyme modified lecithin 40, Miglyol 810 10, vitamin A propionate 5 parts were dissolved in ethanol 20, propylene glycol 10, and water 5. The compn. was heated and dild. to obtain a clear yellow dispersion of microscopic lipid aggregates.

IT 9005-49-6, Heparin, biological studies 25322-68-3,
Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study);
USES (Uses)

(drug carriers contg. micelle-forming membrane lipids and
bilayer-forming lipids and other ingredients)


RN 9005-49-6 HCAPLUS

CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



IT 7440-70-2, Calcium, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(regulating agents for; drug carriers contg. micelle-forming membrane
lipids and bilayer-forming lipids and other ingredients)

RN 7440-70-2 HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:725477 HCAPLUS

DOCUMENT NUMBER: 133:286502

TITLE: Compositions of polyacids and polyethers and methods
for their use in reducing adhesions

INVENTOR(S): Schwartz, Herbert E.; Blackmore, John M.; Cortese,
Stephanie M.; Oppelt, William G.

PATENT ASSIGNEE(S): Fziomed, Inc., USA

SOURCE: PCT Int. Appl., 189 pp.

CODEN: PIXXD2

INDEPENDENT CLAIMS are included for:

- (i) a kit containing the formulation;
- (ii) a patch containing the formulation; and
- (iii) a method of administering an agent to a mammalian body or plant comprising the novel method.

USE - The method is useful for administering an agent to a mammalian body or a plant, for generating an immune response by vaccinating the mammal and for treating inflammatory disease, dermatosis, kidney or liver failure, adrenal insufficiency, aspiration syndrome, Behcet syndrome, bites and stings, blood disorders (cold-hemagglutinin disease), hemolytic anaemia, hypereosinophilic, hypoplastic anaemia, macroglobulinaemia and **thrombocytopenic purpura**), bone disorders, cerebral oedema, Cogan's syndrome, congenital adrenal hyperplasia, connective tissue disorders (lichen, lupus erythematosus, polymyalgia rheumatica, polymyositis and dermatomyositis), epilepsy, eye disorders (cataracts), Graves' ophthalmopathy, hemangioma, herpes infections, neuropathies, retinal vasculitis, scleritis, gastro-intestinal disorders (inflammatory bowel disease, nausea and oesophageal damage), hypercalcaemia, infections, Kawasaki disease, myasthenia gravis, pain syndromes, polyneuropathies, pancreatitis, respiratory disorders (asthma), rheumatoid disease, osteoarthritis, rhinitis, sarcoidosis, skin diseases, alopecia, eczema, erythema multiforme, lichen, pemphigus and pemphigoid, psoriasis, pyoderma gangrenosum, urticaria and thyroid and vascular disorders.

ADVANTAGE - Increasing the applied dose above a threshold level affects both the drug/penetrant distribution and also determines the rate of penetrant transport across the barrier.

Dwg.0/14

L424 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:741894 HCAPLUS
 DOCUMENT NUMBER: 133:313641
 TITLE: Lipid aggregate-forming compositions and their uses
 INVENTOR(S): Leigh, Steven; Leigh, Mathew Louis Steven
 PATENT ASSIGNEE(S): Phares Pharmaceuticals Research N.V., Neth. Antilles
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061113	A1	20001019	WO 2000-GB1361	20000411
W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
EP 1169020	A1	20020109	EP 2000-919049	20000411
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		

PRIORITY APPLN. INFO.: GB 1999-8309 A 19990412
 WO 2000-GB1361 W 20000411

AB Formulations are provided which contain at least one micelle-forming monoacyl membrane lipid either alone or preferably in combination with one

RN 139639-23-9 HCAPLUS
 CN Plasminogen activator, tissue-type (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 10 OF 22 WPIX (C) 2003 THOMSON DERWENT
 ACCESSION NUMBER: 2002-075222 [10] WPIX
 DOC. NO. CPI: C2002-022413
 TITLE: Inhibiting cerebral amyloid angiopathy used for
 treating e.g. Alzheimer's disease comprises contacting
 blood vessel wall cell with amyloid-beta 40
 inhibitor.

DERWENT CLASS: B05
 INVENTOR(S): GERVAIS, F; GREEN, A M
 PATENT ASSIGNEE(S): (NEUR-N) NEUROCHEM INC; (GERV-I) GERVAIS F; (GREE-I)
 GREEN A M
 COUNTRY COUNT: 95
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001085093	A2	20011115	(200210)*	EN	68
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW					
AU 2001084313	A	20011120	(200219)		
EP 1251837	A2	20021030	(200279)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
BR 2000016652	A	20021119	(200305)		
US 2003003141	A1	20030102	(200305)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001085093	A2	WO 2000-IB2078	20001222
AU 2001084313	A	AU 2001-84313	20001222
EP 1251837	A2	EP 2000-993855	20001222
		WO 2000-IB2078	20001222
BR 2000016652	A	BR 2000-16652	20001222
		WO 2000-IB2078	20001222
US 2003003141	A1 Provisional	US 1999-171877P	19991223
		US 2000-747408	20001222

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2001084313	A Based on	WO 200185093
EP 1251837	A2 Based on	WO 200185093
BR 2000016652	A Based on	WO 200185093

PRIORITY APPLN. INFO: US 1999-171877P 19991223; US 2000-747408
 20001222

AN 2002-075222 [10] WPIX

AB WO 200185093 A UPAB: 20020213

NOVELTY - Inhibiting cerebral amyloid angiopathy comprises contacting a blood vessel wall cell with an A beta 40 inhibitor.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for diagnosing cerebral amyloid angiopathy which comprises administering an imageable A beta 40 inhibitor so that the inhibitor contacts cerebral blood vessels which are likely areas for cerebral amyloid angiopathy, and imaging the areas to determine the presence or absence of the inhibitor in the areas.

ACTIVITY - Nootropic; Neuroprotective; Cerebroprotective.

MECHANISM OF ACTION - A beta 40 inhibitor.

Nine week old hAPP transgenic mice were treated for 8 weeks with 3-amino-1-propanesulfonic acid, sodium salt (A) at a concentration of 30 mg/kg. The extent of cerebral amyloid angiopathy (CAA) in brain sections obtained from these animals was qualitatively determined.

The results for the test/comparative were as follows: number of animals in study = 11/16; number of animals with CAA = 10/15; CAA animals/total animals = 10/11; 15/16 and CAA severity = 6/10 (slight deposition); 4/10 (moderate deposition)/5/15 (slight deposition); 9/15 (moderate deposition); 1/15 (severe deposition).

USE - Used for treating disease states characterized by cerebral amyloid angiopathy (claimed), particularly Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis of the Dutch type and hemorrhagic stroke.

Dwg.0/0

L424 ANSWER 11 OF 22 WPIX (C) 2003 THOMSON DERWENT

ACCESSION NUMBER: 2001-123203 [13] WPIX

DOC. NO. CPI: C2001-035816

TITLE: Targeted ultrasound contrast agents comprising a carrier and a particles consisting of a linker, a targeting ligand and inorganic porous particles of 0.05-500 microns in diameter which contain an entrapped gas or liquid.

DERWENT CLASS: A96 B05 P31

INVENTOR(S): CARPENTER, A P; CHEESMAN, E H; GLAJCH, J L

PATENT ASSIGNEE(S): (DUPO) DU PONT PHARM CO; (DUPO) DUPONT PHARM CO

COUNTRY COUNT: 47

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2001005438	A1	20010125	(200113)*	EN	38
RW: AT BE CH CY DE DK EA ES FI FR GB GR IE IT LU MC NL PT SE					
W: AU BR CA CN CZ EE HU IL IN JP KR LT LV MK MX NO-NZ PL RO SG SI SK					
TR UA VN ZA					
AU 9951275	A	20010205	(200128)		
US 6254852	B1	20010703	(200140)		
EP 1200134	A1	20020502	(200236)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO					
SE SI					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001005438	A1	WO 1999-US16804	19990722
AU 9951275	A	AU 1999-51275	19990722
US 6254852	B1	US 1999-356178	19990716

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059516	A1	20001012	WO 2000-US7963	20000323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG EP 1181023 A1 20020227 EP 2000-921450 20000323 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO US 2002010150 A1 20020124 US 2001-843588 20010426				

PRIORITY APPLN. INFO.:

US 1999-127571P P 19990402
 US 1999-472110 A 19991227
 WO 2000-US7963 W 20000323
 US 2000-200457P P 20000428
 US 2000-200637P P 20000428

AB The present invention relates to improved methods for making and using bioadhesive, bioresorbable, anti-adhesion compns. made of intermacromol. complexes of carboxyl-contg. polysaccharides, polyethers, polyacids, polyalkylene oxides, multivalent cations and/or polycations. The polymers are assocd. with each other, and are then either dried into membranes or sponges, or are used as fluids or microspheres. Bioresorbable, bioadhesive, anti-adhesion compns. are useful in surgery to prevent the formation and reformation of post-surgical adhesions. The compns. are designed to breakdown in-vivo, and thus be removed from the body. Membranes are inserted during surgery either dry or optionally after conditioning in aq. solns. The anti-adhesion, bioadhesive, bioresorptive, **antithrombogenic** and phys. properties of such membranes and **gels** can be varied as needed by carefully adjusting the pH and/or cation content of the polymer casting solns., polyacid compn., the polyalkylene oxide compn., or by conditioning the membranes prior to surgical use. Multi-layered membranes can be made and used to provide further control over the phys. and biol. properties of antiadhesion membranes. Membranes and **gels** can be used concurrently. Antiadhesion compns. may also be used to lubricate tissues and/or medical instruments, and/or deliver drugs to the surgical site and release them locally. An examples was given for prepn. of a neutral CM-cellulose-PEG membrane.

IT 14127-61-8, Calcium ion, biological studies 16397-91-4, Manganese ion (Mn²⁺), biological studies 22537-22-0, Magnesium ion, biological studies 23713-49-7, Zinc ion, biological studies
 RL: MOA (Modifier or additive use); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (compns. of polyacids and polyethers and methods for their use in reducing adhesions)
 RN 14127-61-8 HCAPLUS
 CN Calcium, ion (Ca²⁺) (8CI, 9CI) (CA INDEX NAME)

Ca²⁺

RN 16397-91-4 HCAPLUS
 CN Manganese, ion (Mn²⁺) (8CI, 9CI) (CA INDEX NAME)

Mn²⁺

RN 22537-22-0 HCAPLUS
 CN Magnesium, ion (Mg²⁺) (8CI, 9CI) (CA INDEX NAME)

Mg²⁺


RN 23713-49-7 HCAPLUS
 CN Zinc, ion (Zn²⁺) (8CI, 9CI) (CA INDEX NAME)

Zn²⁺

IT 9004-32-4 9004-42-6, Carboxyethyl cellulose
 9004-61-9, Hyaluronic acid 9005-49-6, Heparin,
 biological studies 9007-28-7, Chondroitin sulfate
 9044-05-7, Carboxymethyl dextran 25322-68-3, Peg
 52519-63-8, Carboxymethyl chitin 83512-85-0,
 Carboxymethyl chitosan
 RL: THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (comps. of polyacids and polyethers and methods for their use in
 reducing adhesions)
 RN 9004-32-4 HCAPLUS
 CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)
 CM 1
 CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2
 CRN 79-14-1
 CMF C2 H4 O3



RN 9004-42-6 HCAPLUS
 CN Cellulose, 2-carboxyethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 503-66-2
 CMF C3 H6 O3

HO-CH₂-CH₂-CO₂H

RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9005-49-6 HCAPLUS
 CN Heparin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 9007-28-7 HCAPLUS
 CN Chondroitin, hydrogen sulfate (9CI) (CA INDEX NAME)


CM 1

CRN 9007-27-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 7664-93-9
 CMF H2 O4 S




RN 9044-05-7 HCAPLUS
 CN Dextran, carboxymethyl ether (9CI) (CA INDEX NAME)

CM 1


CRN 9004-54-0
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3

RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)




RN 52519-63-8 HCAPLUS
CN Chitin, carboxymethyl ether (9CI) (CA INDEX NAME)

CM 1

CRN 1398-61-4
CMF Unspecified
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
CMF C2 H4 O3

RN 83512-85-0 HCAPLUS
CN Chitosan, N-(carboxymethyl) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:240920 HCAPLUS

DOCUMENT NUMBER: 132:270087

TITLE: Foamable formulation comprising a foamable gelling agent and a slow-release precipitant

INVENTOR(S): Gilchrist, Tom; Trainer, Eilidh

PATENT ASSIGNEE(S): Giltech Limited, UK

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000019979	A1	20000413	WO 1999-GB3331	19991007
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338337	AA	20000413	CA 1999-2338337	19991007
AU 9962162	A1	20000426	AU 1999-62162	19991007
EP 1117379	A1	20010725	EP 1999-949178	19991007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526398	T2	20020820	JP 2000-573341	19991007

PRIORITY APPLN. INFO.:

GB 1998-21736 A 19981007
 GB 1999-7065 A 19990327
 WO 1999-GB3331 W 19991007

AB There is described a formulation comprising a foamable gelling agent (such as alginate, carrageenan or CM-cellulose **gels**) and a slow-release precipitant therefor. The precipitant is combined with the gelling agent during foaming and stabilizes the foamed form of the gelling agent. Suitable precipitants include calcium salts such as calcium citrate and calcium chloride, or aluminum salts such as aluminum chloride. The increased stability of the foam facilitates sterilization thereof. Further improvements can be obtained by exposing the cured foam to a precipitant applied externally, optionally washing, and then drying the foam. The foam of the present invention is suitable for medical or veterinary use and can include active ingredients for delivery to, for example, a wound site. A **gel** contained water 80 mL, glycerin 25.22, and Keltone HV 6.5 g. To 100 g of the above **gel** was added 2.5 g calcium citrate and the foamed **gel** was spread out onto plastic sheeting. The resultant foam pad was liftable in 15 min.

IT **7440-66-6D**, Zinc, salts, biological studies **7440-70-2D**, Calcium, salts, biological studies **9004-32-4 25322-68-3**, Polyethylene oxide

RL: **THU (Therapeutic use); BIOL (Biological study);**

USES (Uses)

(foamable formulation comprising foamable gelling agent and slow-release precipitant)

RN **7440-66-6** HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN **7440-70-2** HCAPLUS

CN Calcium (8CI, 9CI) (CA INDEX NAME)

Ca

RN 9004-32-4 HCAPLUS
 CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
 CMF C2 H4 O3



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L424 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:141223 HCAPLUS

DOCUMENT NUMBER: 130:163207

TITLE: Use of locally delivered metal ions for treatment of periodontal disease

INVENTOR(S): Roberts, F. Donald; Friden, Phillip M.; Spacciapoli, Peter; Nelson, Eric

PATENT ASSIGNEE(S): Periodintix, Inc., USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9908691	A2	19990225	WO 1998-US16738	19980813
WO 9908691	A3	19990506		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6153210 A 20001128 US 1997-911413 19970814
CA 2301065 AA 19990225 CA 1998-2301065 19980813
AU 9890178 A1 19990308 AU 1998-90178 19980813
EP 1011693 A1 20000628 EP 1998-942041 19980813

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2001515042 T2 20010918 JP 2000-509430 19980813
NO 2000000688 A 20000315 NO 2000-688 20000211

PRIORITY APPLN. INFO.:

US 1997-911413 A 19970814
WO 1998-US16738 W 19980813

AB Periodontal disease can be treated by the administration of metal ions, preferably silver ions, to the site where the microorganisms that cause this disease reside. Administration can be to periodontal pockets or adjacent to exposed tooth roots or alveolar bone during periodontal surgical procedures. The metal ions can be administered in polymeric microparticles, deformable films or microparticles embedded within deformable films. The metal ions are particularly microbiocidal to the bacterial pathogens that are the causative agents of periodontal disease.

IT 7440-66-6, Zinc, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)

(metal ions, locally delivered, for treatment of periodontal disease)

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

IT 9004-62-0, Hydroxyethyl cellulose 9004-64-2,
Hydroxypropyl cellulose 9004-65-3, Hydroxypropylmethyl cellulose
25322-68-3, Polyethylene glycol

RL: THU (Therapeutic use); BIOL (Biological study);

USES (Uses)

(metal ions, locally delivered, for treatment of periodontal disease)

RN 9004-62-0 HCAPLUS

CN Cellulose, 2-hydroxyethyl ether (8CI, 9CI) (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified

CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 107-21-1

CMF C2 H6 O2

HO-CH₂-CH₂-OH

RN 9004-64-2 HCAPLUS

CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9004-65-3 HCAPLUS

CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 67-56-1
CMF C H4 O




CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L424 ANSWER 17 OF 22 WPIX (C) 2003 THOMSON DERWENT
 ACCESSION NUMBER: 1999-302473 [25] WPIX
 DOC. NO. CPI: C1999-088642
 TITLE: Preparation of micro- and nano- **particle**
 delivery system.
 DERWENT CLASS: A96 B04 B07
 INVENTOR(S): PROKOP, A
 PATENT ASSIGNEE(S): (UYVA-N) UNIV VANDERBILT
 COUNTRY COUNT: 22
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9918934	A1	19990422	(199925)*	EN	52
RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE					
W: AU CA JP					
AU 9897991	A	19990503	(199937)		
EP 1021168	A1	20000726	(200037)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9918934	A1	WO 1998-US21455	19981009
AU 9897991	A	AU 1998-97991	19981009
EP 1021168	A1	EP 1998-952243	19981009
		WO 1998-US21455	19981009

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9897991	A Based on	WO 9918934
EP 1021168	A1 Based on	WO 9918934

PRIORITY APPLN. INFO: US 1997-62943P 19971009

AN 1999-302473 [25] WPIX

AB WO 9918934 A UPAB: 20011203

NOVELTY - A method of making particles useful in drug delivery comprises contacting polyanionic polymers with **cations** in a stirred reactor so that the polyanions and the **cations** react to form particles, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a multicomponent system to generate microparticles, composed of a structural (gelling) polymer and a polymer providing mechanical strength and permeability control;

(2) a particle made by the above method comprising of multicomponent core anionic polymers and anionic antigen, where all components of the core are incorporated as an integral part of the complex formed with the receiving bath polycations;

(3) a composition of matter comprising multicomponent core polymers,

where corona polymers also include a charged surface modifier (electrostatic stabilizer) of the same charge as the corona polymers, and in which all corona components are incorporated in one step as an integral part of the complex;

*polyox
alkylene* → (4) a nonionic polymeric surface modifier (steric stabilizer) as part of the corona multipolymeric system, where all corona components are integrated into the outer polymer structure (shell);

(5) a vaccine comprising the particles of (2);

(6) a composition of matter comprising core anionic polymers and anionic antigens (or plasmid DNA or antisense RNA oligonucleotide), all components being incorporated into the ionically formed complex;

(7) a method of processing reactor content to remove unwanted residual reactants comprises sedimenting or centrifuging the reactor contents, collecting microparticles or nanoparticles generated, rinsing the particles in excess water, buffer or cryopreservation solution, separating suspension by sedimentation or centrifugation, repeating rinsing and separation steps and reducing volume of the suspension to about 1/100th of the initial volume;

(8) a method of chemical stabilization of the washed and isolated particles, by reacting particles with a **crosslinking** agent, rinsing in excess of water, buffer, or cryopreservation solution, separating the particles by sedimentation or centrifugation, repeating the rinsing and separation as needed, and reducing the volume of the suspension;

(9) a method of cryoprotecting the washed particles, by suspending the particles in a cryoprotective solution, and lyophilising;

(10) a method of immunization of animals comprising the step of orally delivering an encapsulated antigen in the particles, where the particles are taken up by M-cells in Peyer's patches of the epithelial lining of the upper intestinal tract resulting in an increase in secretory and systemic antibodies in blood;

(11) a method of adjusting the biodegradability of polymeric mixtures, by contacting an enzyme with a **polysaccharide**, and degrading the substrate at physiological conditions in vivo; and

(12) a method of introducing an adjuvant to potentiate an immunogenic effect, by administration of the adjuvant as part of a droplet forming polymeric mixture.

USE - Possible uses of the micro- or nano- particulate product range over the fields of pharmaceuticals, proteins, polymers, and colloids, immunology, and biomedical engineering. They include delivery of drugs generally, antigens and vaccines for immunization of humans and other animals, genes (plasmid DNA), and antisense RNA and DNA oligonucleotides. Some targeting is possible, e.g., by adding moco adhesive polymers to provide sticking to certain mucosal areas; this applies particularly to the M-cells in Peyer's patches in the epithelial lining of the small intestine, to increase delivery of large molecules, e.g., antibodies. It is stated that the particle production operation can be carried out as a continuous, in addition to a batch process.

L424 ANSWER 18 OF 22 MEDLINE

ACCESSION NUMBER: 1999014126 MEDLINE

DOCUMENT NUMBER: 99014126 PubMed ID: 9795015

TITLE: A novel co-crosslinked polysaccharide: studies for a controlled delivery matrix.

AUTHOR: Coviello T; Dentini M; Rambone G; Desideri P; Carafa M; Murtas E; Riccieri F M; Alhaique F

CORPORATE SOURCE: Dipartimento di Studi di Chimica e Tecnologia delle Sostanze Biologicamente Attive. Universita di Roma 'La Sapienza', 00185 Rome, Italy.

SOURCE: JOURNAL OF CONTROLLED RELEASE, (1998 Oct 30) 55 (1) 57-66.

Journal code: 8607908. ISSN: 0168-3659.
 PUB. COUNTRY: Netherlands
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199901
 ENTRY DATE: Entered STN: 19990202
 Last Updated on STN: 19990202
 Entered Medline: 19990119

AB The formulation of a new controlled delivery system, based on a novel type of matrix obtained by the chemical reaction carried out in an aqueous medium on a mixed physical gel of gellan and scleroglucan, is described in this paper. The preparation yielded a new co-crosslinked polysaccharide (CCP) **hydrogel**, bearing carboxylic groups, that showed a sustained release behaviour that can be modulated by means of calcium ions. For the characterization of CCP, diffusion experiments through the swelled **hydrogel** were carried out in different environmental conditions and the release from tablets prepared with CCP and a model drug was evaluated. The addition of CaCl₂ in the formulation of the dosage forms allowed a further marked reduction in delivery rate to be obtained; this effect is to be related to the free ionized carboxylic groups still present in the gellan moiety of CCP. The different behaviour of Ca²⁺ and Na⁺ ions is discussed.

L424 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:267037 HCAPLUS
 DOCUMENT NUMBER: 126:255279
 TITLE: Cosmetic or pharmaceutical compositions containing Filicium extracts
 INVENTOR(S): Bonte, Frederic; Dumas, Marc; Lavaud, Catherine; Massiot, Georges
 PATENT ASSIGNEE(S): Lvmh Recherche, Fr.
 SOURCE: Fr. Demande, 20 pp.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2735982	A1	19970103	FR 1995-7708	19950627
FR 2735982	B1	19970919		
WO 9701346	A1	19970116	WO 1996-FR998	19960627

W: JP, US

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 EP 835121 A1 19980415 EP 1996-924025 19960627

R: CH, DE, ES, FR, GB, IT, LI

PRIORITY APPLN. INFO.: FR 1995-7708 19950627
 WO 1996-FR998 19960627

AB A compn. contg. 0.0001-3% exts. of Filicium, e.g., Filicium decipiens for cosmetic or pharmaceutical uses is described. This compn. stimulates the prodn. of glycosaminoglycans in the skin, thus making it useful for skin- or hair-care preps. The root bark of F. decipiens (54 g), collected in South Africa, was macerated with 500 mL MeOH for 1.5 h. The ext. was boiled for 3 h, cooled, filtered and treated with 500 mL acetone. A ppt. obtained was sepd., dried, purified by dialysis, and the ext. rich in saponins was used for the formulations. A hydrating **gel** was prepd. from the following components: the plant ext. 0.5, EtOH 5, glycerol 4, Carbopol 940 1.3, water and preservatives to 100 g.


IT 7440-66-6, Zinc, biological studies 9004-61-9,
 Hyaluronic acid 25322-68-3, PEG
 RL: BUU (Biological use, unclassified); THU (Therapeutic use);
 BIOL (Biological study); USES (Uses)
 (cosmetic or pharmaceutical compns. contg. Filicium exts.)
 RN 7440-66-6 HCAPLUS
 CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

RN 9004-61-9 HCAPLUS
 CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L424 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:267035 HCAPLUS

DOCUMENT NUMBER: 126:255475

TITLE: Pharmaceutical and cosmetic compositions containing
 extracts of Foetidia species

INVENTOR(S): Bonte, Frederic; Dumas, Marc; Lavaud, Catherine;
 Massiot, Georges

PATENT ASSIGNEE(S): Lvmh Recherche, Fr.

SOURCE: Fr. Demande, 20 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2735981	A1	19970103	FR 1995-7707	19950627
FR 2735981	B1	19970919		
WO 9701345	A1	19970116	WO 1996-FR997	19960627

W: JP, US

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: FR 1995-7707 19950627

AB Pharmaceutical and cosmetic compns. contg. exts. of Foetidia species are
 useful for the stimulation of glycosaminoglycans prodn. in the skin and
 thus moisturizing skin and hair. Methanolic ext. of F. africana bark (49
 g in 500 mL) was pptd. with acetone, filtered, dialyzed against water and
 lyophilized to obtain 724 mg lyophilizate rich in saponins. The above
 ext. at a concn. of 10 .mu.g/mL increased the prodn. of glycosaminoglycans
 by human fibroblasts significantly. A gel contained above ext.
 0.5, ethanol 5, glycerol 4, Carbopol 940 1.3, and water q.s. 100 g.

IT 7439-95-4, Magnesium, biological studies 7440-66-6,
 Zinc, biological studies 9004-61-9, Hyaluronic acid

25322-68-3, Peg

RL: BUU (Biological use, unclassified); THU (Therapeutic use);

BIOL (Biological study); USES (Uses)

(pharmaceutical and cosmetic compns. contg. exts. of Foetidia species)

RN 7439-95-4 HCAPLUS

CN Magnesium (8CI, 9CI) (CA INDEX NAME)

Mg

RN 7440-66-6 HCAPLUS

CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn


RN 9004-61-9 HCAPLUS

CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L424 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:181165 HCAPLUS

DOCUMENT NUMBER: 116:181165

TITLE: Oral osmotic device for delivering nicotine

INVENTOR(S): Place, Virgil A.; Wong, Patric S. L.; Barclay, Brian L.; Childers, Jerry D.

PATENT ASSIGNEE(S): Alza Corp., USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9201445	A1	19920206	WO 1991-US5089	19910718
W: AU, FI, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9182924	A1	19920218	AU 1991-82924	19910718
AU 652952	B2	19940915		
ZA 9105648	A	19920527	ZA 1991-5648	19910718
EP 540623	A1	19930512	EP 1991-913859	19910718
EP 540623	B1	19940914		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06502622	T2	19940324	JP 1991-512955	19910718
ES 2064117	T3	19950116	ES 1991-913859	19910718

CA 2047418	AA 19920124	CA 1991-2047418	19910719
US 5147654	A 19920915	US 1991-793058	19911115
NO 9300134	A 19930121	NO 1993-134	19930115
PRIORITY APPLN. INFO.:		US 1990-557434	19900723
		WO 1991-US5089	19910718

AB An osmotic device for controlled systemic delivery of nicotine (I) through oral mucosal membrane is disclosed. The device is easily retained in the mouth for extended periods of time. The device comprises a semipermeable wall surrounding a compartment contg. a I salt and an alkali metal salt which is capable of reacting with the nicotine salt in the presence of water to form I base. I base is delivered from the compartment through a passageway in the wall. The I salt exhibits good stability and shelf life, while the I base exhibits excellent absorption through oral mucosal membranes. I bitartrate 0.73, Na₂CO₃ 1.50, poly(ethylene oxide) (II) 83.27, HPMC 5.00, Na saccharin 3.00 g and flavors q.s. were mixed and pressed to form a I layer. II 64.5, NaCl 29.0, HPMC 5.0, Mg stearate 0.5 g, and colors q.s. wa pressed to form a layer in contact with the I layer. The semipermeable walls for bilayer 250 mg tablets was made by blending a soln. contg. 78.0 g cellulose acetate in 3550 mL acetone with 320 mL water and 31.2 g PEG, 13.0 g sorbitol, 2.6 g Na saccharin, and flavors q.s. The tablets were coated with the above soln., dried, and two passageways were drilled through the semipermeable wall on the side of the coated tablet adjacent the I layer.

IT 7440-66-6D, Zinc, complexes with nicotine
 RL: BIOL (Biological study)
 (osmotic delivery device for)
 RN 7440-66-6 HCAPLUS
 CN Zinc (7CI, 8CI, 9CI) (CA INDEX NAME)

Zn

IT 9004-32-4, Sodium carboxymethyl cellulose 9004-64-2,
 Hydroxypropyl cellulose 9004-65-3 25322-68-3,
 Polyethylene oxide
 RL: BIOL (Biological study)
 (osmotic delivery device for nicotine contg.)
 RN 9004-32-4 HCAPLUS
 CN Cellulose, carboxymethyl ether, sodium salt (8CI, 9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
 CMF Unspecified
 CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 79-14-1
 CMF C2 H4 O3



RN 9004-64-2 HCAPLUS
CN Cellulose, 2-hydroxypropyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 57-55-6
CMF C3 H8 O2



RN 9004-65-3 HCAPLUS
CN Cellulose, 2-hydroxypropyl methyl ether (9CI) (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 67-56-1
CMF C H4 O




CM 3

CRN 57-55-6
CMF C3 H8 O2



RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), .alpha.-hydro-.omega.-hydroxy- (9CI) (CA INDEX NAME)



L424 ANSWER 22 OF 22 MEDLINE

ACCESSION NUMBER: 88222345 MEDLINE

DOCUMENT NUMBER: 88222345 PubMed ID: 3130902

TITLE: Water content and compression modulus of some heparin-PVA hydrogels.

AUTHOR: Watler P K; Cholakis C H; Sefton M V

CORPORATE SOURCE: Department of Chemical Engineering and Applied Chemistry, University of Toronto, Ontario, Canada.

CONTRACT NUMBER: HL 24020 (NHLBI)

SOURCE: BIOMATERIALS, (1988 Mar) 9 (2) 150-4.
Journal code: 8100316. ISSN: 0142-9612.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 198807

ENTRY DATE: Entered STN: 19900308

Last Updated on STN: 19970203

Entered Medline: 19880712

AB The effects of changes in the heparin-PVA formulation on the water content, compression modulus and molecular weight between cross-links of the resulting gel was determined. Molecular weight between cross-links was calculated directly from the compression modulus and the swelling ratio. Glutaraldehyde and MgCl₂ displayed the effects expected of them as cross-linking agent and catalyst respectively. On the other hand, formaldehyde appeared to be a non-essential component since its absence had little effect on gel properties and its presence did not affect the water content as originally predicted. Understanding the effect of each formulation component on gel properties enables alteration of gel water content and hence permeability for special applications.

FILE 'HOME' ENTERED AT 17:47:44 ON 28 JAN 2003